ArticleBMC gastroenterology2026
Dual-phase T1-mapping (DHR-MAP) for non-invasive assessment of advanced liver fibrosis and moderate hepatitis: a single-center validation study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND &
aimsConventional non-invasive tests (NITs) for chronic liver disease (CLD) conflate fibrosis and inflammation, limiting diagnostic accuracy. We aimed to redefine the pathophysiological basis of key biomarkers and translate these insights into an integrated diagnostic strategy.
methodsIn a critically underpowered retrospective cohort of 99 patients with histologically confirmed CLD, we performed a comprehensive evaluation of FIB-4, MRE, and DHR-MAP. Analytical rigor was ensured through post-hoc power assessment and stringent multiple comparisons correction. Statistical approaches included partial correlation, hierarchical regression, and mediation analysis to establish biomarker specificity. Diagnostic performance and the proposed two-step strategy were validated via 5-fold cross-validation.
resultsOur analysis resolved a fundamental biomarker paradox. FIB-4 was identified as a marker predominantly reflective of inflammatory activity, showing no independent association with fibrosis after controlling for hepatitis (p=0.414). Conversely, MRE and DHR-MAP were established as fibrosis-specific indicators. This mechanistic clarity informed a novel two-step diagnostic framework: For advanced fibrosis (≥F3), initial screening with DHR-MAP+FIB-4 achieved high sensitivity (0.778 in cross-validation), followed by confirmatory MRE providing high specificity (1.000). For moderate hepatitis (≥G2), FIB-4 screening delivered perfect sensitivity (1.000), with subsequent DHR-MAP+FIB-4 confirmation offering balanced accuracy (specificity 0.857). This integrated strategy substantially reduced diagnostic errors compared to single-modality approaches (88.5% net error reduction for fibrosis; 30.4% for hepatitis) in this cohort, although performance metrics require validation in larger, prospectively designed studies.
conclusionsThis study provides a pathophysiological redefinition of key CLD biomarkers, proposing FIB-4 as an inflammation-predominant marker and introducing a novel two-step diagnostic framework that strategically sequences biomarkers based on their specific strengths. The findings-particularly the dissociation of FIB-4 from fibrosis-offer a mechanistic hypothesis and a practical diagnostic template that must be validated in larger, appropriately powered prospective cohorts to assess generalizability and clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.